摘要
目的:探讨芪苈强心胶囊联合达格列净治疗射血分数减低型心力衰竭(HFrEF)的效果及预后。方法:选取赣州市人民医院2022年5月—2023年8月收治的HFrEF患者84例,按随机数字表法分为两组,各42例。对照组予达格列净治疗,试验组予芪苈强心胶囊联合达格列净治疗。对比两组疗效、心肌标志物水平、运动耐力、心室重构指标、不良反应及预后情况。结果:试验组治疗总有效率较对照组高(P<0.05);试验组治疗6个月心肌肌钙蛋白(cTnI)、N-末端脑钠肽前体(pro-BNP)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)均较对照组低,6分钟步行试验(6MWT)、左心室射血分数(LVEF)均较对照组高(P<0.05);两组不良反应发生率对比,差异无统计学意义(P>0.05);试验组预后不良发生率较对照组低(P<0.05)。结论:芪苈强心胶囊联合达格列净治疗HFrEF效果较好,可降低心肌标志物水平,提高运动耐力,抑制心室重构,改善预后,且安全性好。
Objective:To investigate the efficacy and prognosis of Qili Qiangxin Capsules combined with Dapagliflozin in the treatment of heart failure with reduced ejection fraction(HFrEF).Method:A total of 84 patients with HFrEF admitted to Ganzhou People's Hospital from May 2022 to August 2023 were randomly divided into two groups of 42 each using a random number table method.The control group was treated with Dapagliflozin,while the experimental group was treated with Qili Qiangxin Capsules combined with Dapagliflozin.The efficacy,myocardial marker levels,exercise endurance,ventricular remodeling indicators,adverse reactions,and prognosis between two groups were compared.Result:The total effective rate of treatment in the experimental group was higher than that of the control group(P<0.05);cardiac troponin(cTnI),N-terminal pro-brain natriuretic peptide(pro-BNP),left ventricular end diastolic diameter(LVEDD)and left ventricular end systolic diameter(LVESD)in the experimental group were lower than those in the control group after 6 months of treatment,the 6-minute walk test(6MWT)and left ventricular ejection fraction(LVEF)were higher than those of the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05);the incidence of poor prognosis in the experimental group was lower than that in the control group(P<0.05).Conclusion:The combination of Qili Qiangxin Capsules and Dapagliflozin has a good therapeutic effect on HFrEF,which can reduce myocardial marker levels,improve exercise endurance,inhibit ventricular remodeling,improve prognosis,and has good safety.
作者
徐旺
罗刚
梁会英
XU Wang;LUO Gang;LIANG Huiying(Department of Cardiovascular Medicine,Ganzhou People's Hospital,Ganzhou 341000,China;不详)
出处
《中国医学创新》
2025年第18期36-40,共5页
Medical Innovation of China
基金
江西省中医药管理局科技计划项目(2023B0427)。
关键词
射血分数减低型心力衰竭
芪苈强心胶囊
达格列净
预后
Heart failure with reduced ejection fraction
Qili Qiangxin Capsules
Dapagliflozin
Prognosis
